Drugs of the Kallikrein-Kinin System
This special issue belongs to the section "Medicinal Chemistry and Preliminary Screening".
Special Issue Information
Dear Colleagues,
The new MDPI journal Drugs and Drug Candidates is exploring the interest of the kinin community for a Special Issue under the title “Drugs of the Kallikrein–Kinin System”. Many recent and exciting therapeutic developments in the field justify this editorial project. Notably, various novel strategies are being developed to inhibit the formation of bradykinin or block its receptors in the management of hereditary angioedema. Several other applications are currently being investigated. Harnessing controlled kinin formation is also of potential therapeutic interest, as shown by the clinical development of recombinant tissue kallikrein for ischemic stroke and renal disease. Original research papers or review papers are welcome for submission to this Special Issue. Submissions will be rigorously peer-reviewed.
Dr. François Marceau
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Drugs and Drug Candidates is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- bradykinin
- kallikrein
- kinin
- contact system
- B1 and B2 bradykinin receptors
- kininases
- hereditary angioedema
- angiotensin converting enzyme inhibitors
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Published Papers
Drugs Drug Candidates - ISSN 2813-2998